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ARTICLE
Gut microbiota mediates intermittent-fasting
alleviation of diabetes-induced cognitive
impairment
Zhigang Liu 1,7,8✉, Xiaoshuang Dai 2,7, Hongbo Zhang1, Renjie Shi1, Yan Hui 2,3, Xin Jin2,
Wentong Zhang 1, Luanfeng Wang 1, Qianxu Wang1, Danna Wang 1, Jia Wang1, Xintong Tan 1,
Bo Ren 1, Xiaoning Liu 1, Tong Zhao 1, Jiamin Wang1, Junru Pan 1, Tian Yuan1, Chuanqi Chu1, Lei Lan2,
Fei Yin 4, Enrique Cadenas5, Lin Shi 6,8✉, Shancen Zhao2,8✉ & Xuebo Liu 1,8✉
Cognitive decline is one of the complications of type 2 diabetes (T2D). Intermittent fasting
(IF) is a promising dietary intervention for alleviating T2D symptoms, but its protective effect
on diabetes-driven cognitive dysfunction remains elusive. Here, we find that a 28-day IF
regimen for diabetic mice improves behavioral impairment via a microbiota-metabolites-brain
axis: IF enhances mitochondrial biogenesis and energy metabolism gene expression in hip-
pocampus, re-structures the gut microbiota, and improves microbial metabolites that are
related to cognitive function. Moreover, strong connections are observed between IF affected
genes, microbiota and metabolites, as assessed by integrative modelling. Removing gut
microbiota with antibiotics partly abolishes the neuroprotective effects of IF. Administration
of 3-indolepropionic acid, serotonin, short chain fatty acids or tauroursodeoxycholic acid
shows a similar effect to IF in terms of improving cognitive function. Together, our study
purports the microbiota-metabolites-brain axis as a mechanism that can enable therapeutic
strategies against metabolism-implicated cognitive pathophysiologies.
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The prevalence of type 2 diabetes (T2D) is on the riseworldwide1, and cognitive decline is a severe complicationof T2D2,3. The etiology of cognitive impairments resulting
from diabetes is multifactorial, including brain insulin resistance,
cerebral microvascular damage, and neuroinflammation2,4. Pre-
vious research has found that T2D-associated or high-fat-diet-
induced cognitive deficits are connected to brain insulin resis-
tance, glucose uptake decrease, neurotransmitter metabolism
disturbance, and mitochondrial dysfunction5,6.
Recent studies have emphasized the critical impact of gut
microbiota on regulating systemic insulin sensitivity and energy
metabolism via the generation of functional microbial metabolites
in diabetic rodent models and humans7,8. Moreover, gut micro-
biota plays a vital role in linking diet and host physiology and
pathology. Microbiota homeostasis is essential for the main-
tenance of gut health and for modulating cognitive functions via
the regulation of the permeability of the blood–brain barrier,
brain energy homeostasis, and synaptic transmission9–11. It is
noteworthy that interindividual variation of microbiota compo-
sition and microbial metabolites, such as short-chain fatty acids
(SCFAs), 3-indolepropionic acid (IPA), secondary bile acids
(BAs), and serotonin (5-HT), are critically driven by the geno-
type, age, and dietary patterns of the host10,12. They are also
strongly linked to whole body metabolism and function parti-
cularly, and have been shown to have potential neuroprotective
effects. BAs such as tauroursodeoxycholic acid (TUDCA) has
been suggested as a potential agent in preventing amyotrophic
lateral sclerosis and Alzheimer’s diseases (AD)13,14. In addition,
previous research demonstrated that IPA, one of the microbial
deamination metabolites of tryptophan, might possess potential
neuroprotective against β-amyloid-induced neuronal damage via
scavenging free radicals15.
Dietary restrictions have been well reported to be beneficial in
the context of metabolic syndrome and the lengthening of life-
spans, and gut microbiota may play a pivotal role in this16.
Intermittent fasting (IF) regimens represent a periodic dietary
restriction, which have shown to increase lifespan, promote
energy metabolism, and to reduce the risk of developing various
age-related pathologies17–19. It has been suggested that IF could
ameliorate insulin resistance, activate adipose tissue browning,
protect central nervous system autoimmunity, and improve
diabetes-related retinopathy in rodent models, via modulation of
the gut microbiome and microbial metabolites compositions20–22.
Moreover, IF designed as alternate-day fasting has shown to
improve age-related and Alzheimer’s disease (AD)-associated
neuroinflammation, brain structure, and cognitive functions in
animal models23–26. Nonetheless, the protective effects of IF on
the cognitive deficits associated with diabetes remain unclear, and
to what extent the gut microbiota affect brain function is largely
underexplored.
Given emerging reports that link gut microbiota to brain
function and metabolism in relation to IF and health status, we
undertook a comprehensive study to examine the impact of IF
on diabetes-driven cognitive impairment and underlying
mechanisms in db/db mice, a typical T2D rodent model, using a
multi-OMICS analysis of the gut microbiota, plasma metabo-
lome, and brain transcriptome combined with conventional
behavioral tests. To determine the role of gut microbiota in
mediating the protective effects of IF on cognitive deficiency,
we also examined behavioral alterations in diabetic mice in
which the gut microbiota was removed by antibiotics treatment.
Our findings suggest that gut microbiota/metabolites mediate
the neuroprotective actions of IF on diabetes, thus highlighting
the potential of modulating the gut microbiota as an effective
intervention for metabolism-implicated neurodegenerative
diseases.
Results
IF suppressed insulin resistance and cognitive impairment.
Three-month-old db/db mice were fed either an ad libitum diet or
fasted at 24 h intervals for 28 days (Fig. 1a). Compared with the
db/m group, the littermate control mice, the food/energy intake
was higher in db/db mice (Fig. 1c, d) (ANOVA with Tukey’s test,
p < 0.01). IF decreased the bodyweight of db/db mice (Fig. 1b)
(ANOVA with Tukey’s test, p < 0.01) without changing their total
energy intake (Fig. 1c, d). In addition, IF treatment substantially
reduced water intake per day in db/db mice (Supplementary
Fig. 1A) (ANOVA with Tukey’s test, p < 0.01) with less urine at
the end of the treatment (Supplementary Fig. 1A).
The effects of IF on insulin resistance in the db/db mice were
assessed with an insulin-tolerance test on day 28 (Fig. 1e).
Specifically, IF treatment increased insulin sensitivity in db/db
mice by suppressing fasting glucose levels (54.8% lower) and
fasting insulin levels (29.8% lower), compared with ad libitum fed
mice (Fig. 1f, g). The HOMA-IR values, which reflected insulin
resistance, were lowered after IF treatment in db/db mice
(Fig. 1h). Furthermore, IF significantly reduced the mass of
epididymal white adipose tissues (eWAT) and the size of
adipocytes (Supplementary Fig. 1B–D) (ANOVA with Tukey’s
test, p < 0.01). Morris water-maze tests were performed to assess
the effects of IF on the cognitive impairment inherent in the
diabetic mice. IF decreased escape latency in the 5-day navigation
test, indicating that the improved cognitive deficits of db/db mice
(Fig. 1i; Supplementary Fig. 1E). On the probe trial day, IF
elevated the time spent in the target quadrants (ANOVA with
Tukey’s test, p < 0.05) in db/db mice, reflecting an increase in the
spatial memory of diabetic mice (Fig. 1j). The results from the
elevated plus maze, a behavioral test of anxiety, suggesting that IF
treatment improved anxious behavioral and locomotor activity in
db/db mice (Supplementary Fig. 1F–H).
IF improved synapse ultrastructure and insulin signaling. The
ultrastructure of synapses in the hippocampus—the major region
of the brain involved in cognition and memory—was examined,
after the mice were killed. An analysis of postsynaptic density
(PSD) (Fig. 2a) revealed that both the length and width of PSD
were elevated in db/db-IF mice compared with the db/db group
(Fig. 2b, c) (ANOVA with Tukey’s test, p < 0.01).
Insulin signaling was assessed in the hippocampus in order to
evaluate whether IF could ameliorate brain insulin resistance. IF
increased the IRS1- Tyr896/IRS1 and Akt phosphorylation,
indicating that it stimulated the hippocampal insulin signaling
pathway (Fig. 2d). We also observed that IF treatment enhanced
the expression of BDNF, a neurotrophic factor involved in
maintaining neuronal survival and synaptic function, and the
phosphorylation of ERK/CREB, an upstream signaling of BDNF
synthesis, compared with db/db mice (Fig. 2e) (ANOVA with
Tukey’s test, p < 0.05). Likewise, the expressions of PSD-95, a
scaffolding protein in the excitatory postsynaptic density, was also
increased in IF-treated mice hippocampi (Fig. 2e), in line with
PSD ultrastructural alterations.
It is also worth noting that NFκB, a major transcriptional
factor mediating inflammation27, was activated in the hippo-
campus of diabetic mice (Supplementary Fig. 2). IF treatment
suppressed NFκB activation and downregulated the phosphoryla-
tion of JNK/p38 and protein expressions of Iba-1, a well-known
marker of microglial activation (Supplementary Fig. 2).
IF promoted mitochondrial biogenesis in the hippocampus.
RNA sequencing on mice hippocampi was performed in order to
identify the key biological processes and pathways regulated by IF
in the hippocampus (Supplementary Data 1). After mapping
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310.85 Gb clean RNA-SEQ reads of all mice against the Mus
musculus genome, we detected 27,094 genes (including 1345 new
predicted genes with no annotation) with a FPKM value (Sup-
plementary Data 2). Among them, 1181 genes were found to be
highly expressed in db/db-IF mice compared with db/db and db/
m mice, using differentially expressed gene (DEG) analysis (DEG-
group 1 genes) (FDR-p < 0.05) (Fig. 3a; Supplementary Data 3),
most of which were enriched in mitochondrial-related GO terms.
The GO terms analysis of those genes that had lower expression
in db/db mice (DEG-group 6 genes) indicated the respiratory
chain and mitochondrial fission/translation biological process
were dysregulated in db/db mice, which suggested abnormal
mitochondrial metabolism in diabetic mice hippocampus. How-
ever, the related mitochondria-related genes expressions were
corrected by the IF regimen (Fig. 3a). Moreover, the expressions
of 483 genes in db/db mice hippocampus were comparable with
those levels in db/m mice after IF treatment (DEG-group 3 and
group 6) (FDR-p < 0.05), and 31.3% of these genes were even
significantly higher (60 genes) or lower (91 genes) expressed than
db/m mice (Supplementary Data 3). IF also elevated genes related
to the KEGG pathway of oxidative phosphorylation (OXPHOS)
via upregulating mitochondrial genes expression (Fig. 3b). The
KEGG analysis of these genes were also indicated that IF treat-
ment improved energy metabolism-related genes expressions in
OXPHOS that were downregulated in db/db mice (Supplemen-
tary Fig. 3B).
To identify the biological networks affected by IF regimens, we
performed a weighted gene co-expression network analysis
(WGCNA) using all 27,094 genes in 31 samples, and 5 modules
were identified that contained functionally and biologically linked
genes (Supplementary Fig. 3C). Of note, the “MEbrown” module
was highly positively correlated with the IF regimen (r= 0.892,
p= 2e-11) (Supplementary Fig. 3D), which consisted of 1044
genes (88.40%) identified using DEG (Supplementary Fig. 3E).
We identified 49 hub genes (FDR-p < 0.01) with high inter-
connectivity and intra-connectivity in the module (Supplemen-
tary Fig. 3E). Importantly, the majority of identified hub genes
were enriched in the mitochondria and metabolism-related GO
terms, and KEGG pathways of oxidative phosphorylation,
Huntington’s disease, AD, Parkinson’s disease (Fig. 3c, d;
Supplementary Data 5).
Consistent with the results from the RNA-sequencing analysis,
the qPCR analysis confirmed that the mitochondrial and
metabolic genes expressed were upregulated by IF in db/db mice
(Supplementary Fig. 3F). As an indicator of mitochondrial
biogenesis, the mtDNA/nDNA ratio in the hippocampus was
increased by IF in db/db mice (Fig. 3g) (ANOVA with Tukey’s
test, p < 0.01), suggesting that the upregulated mitochondrial
genes were likely a consequence of increased mitochondria mass.
We then sought to examine PGC1α and AMPK/mTOR protein
expression to uncover the potential underlying mechanism of
upregulating mitochondrial biogenesis in the db/db-IF group
(Fig. 3e). IF led to a significant increase in the protein expression
of PGC1α, the master regulator of mitochondrial biogenesis; this
established a strong correlation with mitochondrial-related gene
upregulation (Supplementary Fig. 3F). In line with previous
studies, IF increased the activation of AMPK, a kinase mediating
cellular energy metabolism sensitive to fasting status (Fig. 3e) and
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Fig. 1 Intermittent fasting alleviated insulin resistance and cognitive impairment in db/db mice. a Timeline depicting the diet of IF or ad libitum in each
group; b bodyweight (n= 10 mice per group); c energy intake; d food intake; e insulin-tolerance test; f fasting glucose; g fasting insulin level (n= 7 mice per
group); h HOMA-IR (n= 7 mice per group). The animals’ cognitive functions were assessed by the Morris water-maze test as described in “Methods”
(n= 10 mice per group); i escape latency (s), and j the time spent in the target quadrant (s) during the probe trial were recorded. Data presented as mean
± SEM. *p < 0.05, **p < 0.01, compared with db/m group, #p < 0.05, ##p < 0.01 compared with the db/db group. Significant differences between mean
values were determined by one-way ANOVA with Tukey’s multiple comparisons test. See also Supplementary Fig. 1. Source data are provided as a Source
Data file.
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inhibited the phosphorylation of mTOR, a eukaryotic cell
nutrient sensor that plays an essential role in regulating
mitochondrial quality control and OXPHOS process28.
IF-restructured gut microbiota and microbial metabolites. The
integrity of the gut barrier is critical to maintaining gut perme-
ability and preventing endotoxemia, and is also related to diabetes
and its complications21. It has also been reported that increased
endotoxemia from increased gut permeability can increase
inflammation, which triggers impaired glucose tolerance29. We
thus investigated the effects of IF on gut barrier integrity, by
assessing the villi length, the thickness of the muscularis, and the
numbers of goblet cells. The results showed that IF increased the
villi length and the muscularis thickness in diabetic mice, but had
no influence on the numbers of goblet cell (Supplementary
Fig. 4A–D). Moreover, the permeability of the colon was assessed
with a use of Ussing Chamber, and we observed that IF prevented
gut leakage accompanied with a decline in plasma LPS levels
(Supplementary Fig. 4G, H) (ANOVA with Tukey’s test, p < 0.01).
The expression of claudin-1, a tight-junction protein in gut bar-
rier30, was also elevated in db/db-IF colon tissue (Supplementary
Fig. 4A, E, F), in line with the intestinal permeability alteration.
Gut microbiota composition was determined from fecal
samples of the respective mice on day 0 (baseline level) and
day 28 using bacterial 16S rRNA gene v3–v4 amplicon
sequencing. Specifically, the microbiome alpha diversity signifi-
cantly increased after a 28-day IF treatment even though the total
number of OTUs remained at the same level initially (Fig. 4a)
(Kruskal–Wallis, p < 0.05). The unweighted Unifrac distance of
the db/db-IF mice on the day 28 was different from other groups,
which indicates that the IF regimen changed β-diversity in the
meantime (Fig. 4b) (p < 0.05). Considering time as a background
effect, different diets and murine genotype were major factors in
the shaping of gut microbiome and explained 5.9% and 7.7% of
the total variance, respectively (Fig. 4c). IF treatment did not
totally overturn the influence of diabetes with decreased relative
abundance of Allobaculum and Bifidobacterium in both db/db
a
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mice (Fig. 4d). However, IF treatment improved Lactobacillus and
butyrate-producing Odoribacter while decreased Enterococcus,
Streptococcus, and unknown Enterococcaceae (Fig. 4d; Supple-
mentary Data 6) (ANCOM, p < 0.05). Compared with the db/db
group, bacteria from Candidatus Arthromitus, Rummeliibacillus,
unknown Enterococcaceae, and Leuconostocaceae were lower in
both db/m and db/db-IF groups (Fig. 4d).
Moreover, the identified IF-related genera were correlated with
the obesity and cognition-associated blood glucose and body-
weight. Specifically, Candidatus Arthromitus and an unknown
Leucostocaceae genera were positively correlated with blood
glucose (Pearson’s coefficient= 0.52 and 0.72, respectively, p <
0.05). An unknown Enterococcaceae genera was positively
correlated with bodyweight (Pearson’s coefficient= 0.59, p <
0.05) (Supplementary Fig. 5B, Supplementary Data 7).
Considering the mice gene-type effect, we evaluated the
microbiota composition of the db/db mice and the db/db-IF
group on day 28. We found that a total of 17 zOTUs affected by
IF, 5 of which belonged to Lactobacillus (Fig. 4e). Meanwhile, a
PICRUSt analysis revealed 11 differently abundant KEGG gene
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shown on the right for each cluster. The p-values of GO terms were determined on the WebGestalt website; b KEGG of oxidative phosphorylation (FDR-p <
0.05) of group 1 (1181) and group 4 (688) genes based on DEG analysis. Pink represents upregulation during Intermittent fasting. Blue represents
downregulation during Intermittent fasting. c Network and GO annotation of 49 brown-module hub genes (upregulated when intermittent fasting, r[ME
and gene] > 0.8, r[trait and gene] > 0.85, FDR-p < 0.01) in WGCNA analysis (edge weights > 0.4). The p-values of GO terms were determined on the
WebGestalt website; d KEGG analysis (FDR-p < 0.05) of the brown-module hub genes in the WGCNA analysis. The p-values of KEGG analysis were
determined on the WebGestalt website; e, f Western blots of mTOR/AMPK/PGC1α signaling (n= 3 mice per group); g mitochondrial DNA levels in brain
tissue (n= 8 mice per group). Data of f, g presented as mean ± SEM. *p < 0.05, **p < 0.01, compared with the db/m group, #p < 0.05, ##p < 0.01 compared
with the db/db group. Significant differences in d, g between mean values were determined by one-way ANOVA with Tukey’s multiple comparisons test.
The boxplot elements are defined as following: center line, median; box limits, upper and lower quartiles; whiskers, 1.5 × interquartile range. See also
Supplementary Fig. 3 and Supplementary Data 1–5. Source data are provided as a Source Data file.
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Fig. 4 Gut microbiome and plasma metabolome analysis of intermittent fasting-treated db/db mice. a Total number of observed OTUs in db/m, db/db,
and db/db-IF (n= 11, 10, 11 mice in each group, respectively). Significant differences between day 0 and day 28 were tested by Kruskal-Wallis test.
Significant differences between treatment groups were tested by Wilcoxon rank-sum test (*p < 0.05). b Principal coordinate analysis (PCoA) based on
unweighted Unifrac distance and permutational manova (adonis) were used to test the difference in gut microbiota composition and diversity between
groups (the colored ellipse denotes an 80% confidence within each group. c Constrained analysis of principal coordinate (CAP) of diet and mice gene type
was performed on cumulative sum scaling (CSS) normalized Bray Curtis distance after the removing time effect. The permutational ANOVA-like test for
constrained respondence analysis (ANOVA.CCA) was applied to examine the influence of diet and mice gene type on the matrix. d Relative abundance of
different genera was identified by an analysis of composition of microbiome (ANCOM) on day 28 (FDR-p < 0.05). Wilcoxon rank-sum test was adopted for
comparisons between groups (*p < 0.05, **p < 0.01, compared with the db/dm group, #p < 0.05, ##p < 0.01 compared with the db/db group). e A Z-score
scaled heatmap of different zOTUs identified by ANCOM between db/db-IF and db/db on day 28 with FDR-p < 0.05. f A Z-score scaled heatmap of
different pathways identified by an extraction of differential gene expression (Edge) between db/db-IF and db/db on day 28 with FDR-p < 0.1. g The
difference in microbial metabolites in db/db and db/db-IF mice (n= 10 mice per group). Microbial metabolites that were up/downregulated after IF
treatment. Differences were examined by Wilcoxon rank-sum test (*p < 0.05, **p < 0.01). IPA 3-indolepropionic acid, CA cholic acid, DCA deoxycholic
acid, MCA muricholic acid, TUDCA tauroursodeoxycholic acid, 12-HEPE 12-hydroxyeicosapentaenoic acid. The boxplot elements are defined as following:
center line, median; box limits, upper and lower quartiles; whiskers, 1.5 × interquartile range. See also Supplementary Figs. 4–6 and Supplementary Data 6–
9. Source data are provided as a Source Data file.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14676-4
6 NATURE COMMUNICATIONS | (2020)11:855 | https://doi.org/10.1038/s41467-020-14676-4 | www.nature.com/naturecommunications
pathways (FDR-p < 0.1). Among them, the primary and second-
ary bile acid biosynthesis were abundant in the db/db-IF group
(Fig. 4f; Supplementary Data 8).
IF treatment demonstrated a great impact on gut microbiota,
raising our interest in investigating whether and how, it could affect
circulating microbial metabolites, whose levels were primarily
modulated by the gut microbiota. This investigation could provide
novel insights into the mechanism underlying the observed benefits
of IF treatment on host metabolism. Overall, the untargeted
metabolite profiling of plasma samples revealed marked changes in
numerous metabolites after 28 days of IF treatment in db/db mice
(Supplementary Fig. 5C, D). The number of metabolite features that
differed between treatments were 540 and 491 out of 5604 and 5230
in a data set collected from the reverse-phase chromatography
positive (RP+) and negative polarity (RP−), respectively (Supple-
mentary Fig. 5E, F) (FDR-p < 0.05). Specific emphasis was placed
on an a priori defined subset of 23 microbial metabolites whose
levels were primarily modulated by the abundance of gut
microbiota (Supplementary Data 9) to demonstrate a direct link
between IF treatment, gut microbiota, and metabolome12. Among
these metabolites, IF increased plasma levels of 5-HT, tryptophan,
p-hydroxyphenyl acetic acid, N-acetyl tryptophan, cinnamoylgly-
cine, IPA, and bile acids, e.g., cholic acid (CA), deoxycholic acid
(DCA), muricholic acid (MCA), and TUDCA compared with ad
libitum fed db/db mice (Wilcoxon rank-sum test, p < 0.05). In
contrast, tyrosine, phenylacetylglycine, phenylpropionylglycine, p-
cresol, and p-cresol sulfate, as well as 12-hydroxyeicosapentaenoic
acid (12-HEPE) were lower in the db/db-IF group than the db/db
group (Fig. 4g) (Wilcoxon rank-sum test, p < 0.05).
In addition, we also analyzed concentrations of short-chain fatty
acids (SCFAs) in fecal samples, which have shown to protect gut
barrier function and regulate insulin sensitivity31,32. After the 28-
day treatment, IF improved levels of acetate, propionate, and
butyrate in db/db mice (Supplementary Fig. 4I–K) (ANOVA with
Tukey’s test, p < 0.05). It should be noted that SCFAs concentra-
tions were low in plasma, and thus could not be accurately detected
using untargeted metabolomics in the current setting.
Integrated multi-OMICs analysis on IF regimen. Having
identified different omics signatures that were upregulated or
downregulated by IF in diabetic mice, the next step was to assess
the interplay across gene expressions in the hippocampus (Fig. 3),
gut microbiota compositions (Fig. 4), and microbial metabolites
(Fig. 4), in relation to the observed impact of IF treatment on
cognitive deficiencies in mice (Fig. 2). The multi-OMICs data set
was integrated using the data integration analysis for biomarker
discovery using a latent component method for OMICs (DIA-
BLO). DIABLO is a multivariate dimension reduction dis-
criminant analysis method designed to identify biologically
relevant and highly correlated signatures from various OMICs
techniques33 (Fig. 5; Supplementary Information).
Prior to multi-OMICS integration, we first evaluated whether
the IF-upregulated hub genes n= 36), the IF-altered OTUs (n=
17), the predefined plasma microbial metabolites (n= 23), and
three fecal SCFAs, i.e., acetate, butyrate, and propionate could
predict the IF status of mice in a multivariate manner12.
Predictive modeling was conducted using a partial least square-
discriminant analysis incorporated into a repeated double cross-
validation framework (rdCV-PLSDA), which effectively mini-
mized the risk of statistical overfitting34. A significant separation
between db/db and db/db-IF mice was achieved with a predictive
accuracy of 100%, 90%, and 95% for hub genes, OTUs, and
metabolites, respectively (Fig. 5a). The optimal selected number
of latent components was 1 for each of the OMICs data sets. The
predictive ability of the constructed models outperformed those
of 1000 permuted models, demonstrating the robustness and
validity of predictive models in discriminating db/db from db/db-
IF using parsimonious sets of OMICs signatures with great
generalizability (Student’s t test, p < 0.05, Supplementary Fig. 6B).
The integrative modeling was then performed on the multi-
OMICs signatures, and one latent component comprised ten key
predictors from each of OMICs data sets was identified,
contributing a great separation between db/db and db/db-IF
(Fig. 5b). The optimally selected key predictors included several
species of gut microbiota, i.e., Lactobacillus, Bacteroides, and
Facklamia, microbial cometabolites, i.e., bile acids, IPA, 5-HT,
tryptophan, hydroxytryptophol, and indoxyl sulfate, and genes
enriched in mitochondrial, ribosomal or metabolic-related GO
terms (Fig. 5b, c; Supplementary Fig. 6C). Key predictors were
also highly correlated (Fig. 5d).
Gut microbiota are required for the beneficial effects of IF. To
demonstrate the crucial role of gut microbiota in mediating
inherent diabetic cognitive deficits, we sought to investigate
whether the observed beneficial effects of IF could be affected
after removing the gut microbiota in db/db mice.
An antibiotics cocktail treatment was applied to establish the
role of the microbiota in the neuroprotection afforded by IF35.
The mice were administrated with antibiotics in the drinking
water starting 14 days before the 4-week IF regimen and
throughout the experiment, and the behavioral changes were
assessed after 28 days (Supplementary Fig. 8A, B). The antibiotics
treatment weakened the weight loss effects of the IF treatment
(Fig. 6a) (ANOVA with Tukey’s test, p < 0.05). The antibiotics
treatment had no impact on the eWAT weight, but enhanced the
liver and cecum weight (Supplementary Fig. 8E–G). Both IF and
antibiotics treatment reduced food and water intake in db/db
mice (Supplementary Fig. 8C, D). However, the administration of
antibiotics had no impact on the beneficial effects of IF on insulin
resistance (Supplementary Fig. 8H–K). Of note, the cognition
improvement assessed using the Morris water-maze test asso-
ciated with IF was partly abolished by antibiotics treatment, with
longer escape times on the 5th day of the test and lower times in
the target quadrant on the probe test day (Supplementary Fig. 6B;
Fig. 8L, M). Moreover, mitochondrial biogenesis—upregulated in
the db/db-IF mice—was abrogated with antibiotics treatment
(Fig. 6c). An analysis of PSD (Fig. 6d, e) revealed that the width of
PSD—elevated in db/db-IF mice—was reduced by antibiotics
treatment (ANOVA with Tukey’s test, p < 0.01). These results
together indicate that the removal of microbiota partly abolishes
the protective effects of IF on cognitive function.
In addition, compared with the db/db-IF group, we found that
the removal of gut microbiota by the antibiotics treatment
significantly reduced plasma IPA and fecal SCFAs in db/db mice
(Supplementary Fig. 9, Supplementary Data 10) (ANOVA with
Tukey’s test, p < 0.01).
Microbial metabolites improved the cognitive function. An
additional animal study was conducted to investigate the role of IF-
regulated microbial metabolites, in particular, IPA and SCFAs that
were reduced in the antibiotics-treated group, in improving cog-
nitive deficits. Besides, the effects of peripheral 5-HT and TUDCA
on cognitive function were also examined, since these metabolites
were elevated in the IF group in this study (Fig. 4g). Previous studies
have also reported the potential of their neuroprotective
effects13,14,36. Administration of all these metabolites individually
improved cognitive function and insulin sensitivity in db/db mice
(Fig. 6g; Supplementary Fig. 10C–H) (ANOVA with Tukey’s test,
p < 0.05). Consistent with the beneficial effects of IF treatment,
administration of these metabolites also enhanced mitochondrial
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biogenesis and protected the ultrastructure of synapses (Fig. 6h–j).
Moreover, treatment of TUDCA but not other tested metabolites
suppressed the bodyweight gain in db/db mice (Fig. 6f). Besides, all
the metabolites treatment had no influence on food intake and
water intake of the db/db mice (Supplementary Fig. 10A, B).
Although the dosage of the metabolites treatment was higher than
that in IF regimen group mice, these results partly evaluate the
causation and the roles of these metabolites in during IF regimen.
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Discussion
A number of studies has shown beneficial effects of IF on diabetes
and its complications through the restructuring of gut micro-
biota20,21. However, whether IF could alleviate diabetes-related
cognitive deficits and the role played by gut microbiota is still
unclear, highlighting an urgent need to investigate the mechan-
isms underlying how IF improves cognitive function. This study
has demonstrated for the first time that a 28-day IF treatment
alleviated diabetes-induced cognitive impairment via a
microbiota–metabolites–brain axis, benefiting from comprehen-
sive investigations on diabetic mice behavior/synaptic structure,
mitochondrial/energy metabolism-related signaling, and an inte-
grated analysis of multi-OMICs.
IF improved cognitive function and spatial memory in diabetic
mice as evidenced from a Morris water-maze test, a de-facto
standard and valid cognitive assessment37,38. Our previous study
found that the impairment of brain insulin signaling led to glu-
cose hypometabolism, disturbed tricarboxylic acid (TCA) cycle,
as well as altered neurotransmitter levels and a decline in long-
term potentiation (LTP)39. This finding provided an essential link
between brain energy metabolism and cognitive function. Here,
we found that IF stimulated IRS1/Akt signaling and its related
ERK/CREB/BDNF neurotrophic signaling, and IF inhibited the
NFκB/JNK inflammatory pathways (Fig. 2; Supplementary
Fig. 2). Consistently, the increase of postsynaptic protein PSD-95
and the improvement of the ultrastructure of synapses in the
hippocampus further demonstrated the benefits of an IF regimen
on synaptic function. Further research is needed to determine the
effects of IF on neuronal glucose uptake/metabolism and synaptic
transmission in diabetic models via PET/CT/NMR and LTP assay
measurements, respectively.
An integrated analysis of multi-OMICs data revealed strong
links between the alterations of microbial metabolites in circu-
lation and the IF-induced changes of the microbiome profile and
hippocampus mitochondrial and energy metabolism-related
gene expression. These findings suggest the beneficial effects
of 28-day IF on diabetes-induced cognitive functions via the
gut–metabolism–brain axis (Fig. 5), which to the best of our
knowledge, has not been reported before.
Herein, we observed that a 28-day IF regimen improved gut
barrier integrity and decreased plasma LPS level, which could
partly explain how IF reduces neuroinflammatory responses. IF
also altered microbiome diversity in diabetic mice, accompanied
with altered bacteria abundance, enhancing the abundance of
Lactobacillus (Fig. 4). The effect of IF on gut microbiota has been
well reported20–22. However, the restructuring effect of IF on gut
microbiota may be different, due to the variance in animal strains,
housing condition, baseline microbiota profiles, and feeding
periods. Li et al. reported that an every-other-day fasting regimen
increased the OTU abundance of Firmicutes, and at the same time
decreased the majority of other phyla in the fecal contents of male
C57BL/6N mice20. IF also enriched Lactobacillaceae, Bacter-
oidaceae, and Prevotellaceae families in the stool samples of
female C57BL/6J fed every other day22. Intriguingly, a recent
study of IF on db/db mice fecal microbiota composition found
that a 7-month IF regimen led to the enrichment in Lactobacillus
and the reduction of Akkermansia21, which is consistent with our
findings.
The IF-restructured gut microbiota led to alterations in the
microbial metabolites in plasma, which might further explain
how IF alleviates cognitive impairment in diabetic mice. The
PICRUSt analysis found that the several microbes-related meta-
bolism pathways including primary/secondary bile acid biosyth-
esis were altered after IF regimen (Fig. 4f). However, PICRUSt has
its autologous defects on account of the availability of appropriate
reference genomes and undetectable resolution of 16S rRNA
sequences on strain variation. In this study, using metabolome
analysis, we found that IF increased plasma levels of BAs
including CA, TUDCA, MCA, and DCA, and these BAs were
correlated with IF affected gut microbiome and transcriptome in
the hippocampus. Moreover, administration of TUDCA also
improved the cognitive impairment in db/db mice (Fig. 6). These
findings suggest BAs play a role in microbiota–metabolites–brain
axis in relation to cognitive impairment in diabetic mice. In line
with our study, a long-term IF treatment prevented diabetic
microvascular complications by improving plasma TUDCA21.
The dietary-induced dysregulation of BA synthesis was found to
be related to neuroplasticity impairment40. A recent human study
has also reported a strong association between BA profiles and
cognitive function, with the decreased plasma concentration of
CA correlating particularly with AD progression41. In addition,
BA homeostasis is essential for normal glucose/lipid homeostasis,
which may partly explain why the energy metabolism-related
genes were highly expressed in the db/db-IF group42,43.
Other important microbial metabolites altered by IF treatment
in db/db mice include tryptophan and its metabolites 5-HT and
IPA. Tryptophan is not only an essential amino acid for protein
synthesis but also is the precursor for a number of neuroprotective
metabolites10,44. Gut microbiota plays a critical role in regulating
the synthesis of 5-HT, a well-known key hormone/neuro-
transmitter of the gut–brain axis in regulating mood and cogni-
tion45. Interestingly, we found that IF increased 5-HT levels and
suppressed anxiety in db/db mice (Fig. 1f–h; Supplementary
Fig. 4G). We found that IF regimen enriched Lactobacillus, 5-HT
Fig. 5 Strategy and model performance of the integrative modeling on multi-OMICS in relation to IF treatment. a The performance of predictive models
for three OMICs signatures on IF status. OMICs signatures include: 36 IF-upregulated hub genes from the IF-related brown module that was identified
using WGCNA; 17 OTUs that were found to be influenced by IF treatment; 26 priori defined sets of microbial metabolites, including 23 plasma metabolites
and 3 SCFAs measured in fecal samples. For each OMICs data set, multivariate predictive modeling was conducted using partial least square-discriminant
analysis incorporated into a repeated double cross-validation framework (rdcv-PLS). Prediction performance is shown in downstream figures: each swim
lane represents one mice sample. For each sample, class probabilities were computed from 200 double cross-validations. Class probabilities are color
coded by class and presented per repetition (smaller dots) and averaged over all repetitions (larger dots). Misclassified samples are circled. Predictive
accuracy was calculated as a number of correctly predicted samples/total number of measured samples. b The model performance of DIABLO integrative
modeling on OMICs signatures in relation to IF. The use of DIABLO maximized the correlated information between multiple data sets, i.e., genes, OTUs and
metabolites, while optimally identifying in a parsimonious set of key OMICs variables relevant for IF status, i.e., ten key predictors from each of OMICs data
sets. Scatter plots depicting the clustering of groups, i.e., db/db and db/db-IF, based on the first component of each data set from the model showed a
significant separation between groups. A scatterplot displays the first component in each data set (upper diagonal plot) and Pearson correlation between
components (lower diagonal plot). c The Circos plot shows the positive (negative) correlation, denoted as brown (gray) lines, between selected multi-
OMICs features. d A clustered image map (Euclidean distance, complete linkage) of the multi-OMICs signature. Samples are represented in rows, selected
features on the first component in columns. See also Supplementary Fig. 7. Source data are provided as a Source Data file. Detailed procedure and R code
are provided in the Supplementary Information.
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and hippocampus gene expressions, supporting the previously
reported effects of Lactobacillus genera on peripheral 5-HT
synthesis and alleviating behavior impairments46 (Fig. 5). More-
over, IPA, a microbial deamination metabolite of tryptophan, is a
potent neuroprotective antioxidant. Higher plasma concentration
of IPA was associated with lower type 2 diabetes risk in a recent
study44. It has also been well reported for its role in preventing
neuronal damage15. Consistently, we also found that IPA and 5-
HT treatment significantly attenuated cognitive deficits in diabetic
mice (Fig. 6). Taken together, our findings indicated that an IF
regimen improved brain energy metabolism and cognitive func-
tion via restructuring gut microbiota and metabolites.
Notably, these IF-improved neuroprotective microbial meta-
bolites are highly correlated with mitochondrial biogenesis and
energy metabolism-related gene expression in the hippocampus,
which could shed light on a new mechanism for how IF alleviated
diabetes-induced cognitive deficits (Fig. 5). Mitochondria, as the
powerhouses for eukaryotic cells, generate ATP via OXPHOS to
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Fig. 6 The effects of antibiotics and microbial metabolites on the cognitive functions of IF-treated db/db mice. The mice were administrated with
antibiotics in the drinking water starting 14 days before the 4-week IF regimen and throughout the experiment (the detailed antibiotics treatment is as
described in “Methods”). a Bodyweight gain (g) (n= 7 mice and 13 mice in ad libitum feeding and IF regimen groups, respectively). b Escape latency (s) in
place navigation test (the 5th day). c Mitochondrial DNA levels in brain tissue (n= 7 mice per group); d width of PSD. e Representative images of
ultrastructure of synapse (n= 6 slices per group). Data presented as mean ± SEM. *p < 0.05, **p < 0.01, compared with the db/db group, &p < 0.05, &&p <
0.01, compared with the db/db- antibiotics group, #p < 0.05, ##p < 0.01 compared with the db/db-IF group. Significant differences between mean values
were determined by two-way ANOVA (IF regimen and antibiotics treatment as two factors) with Tukey’s multiple comparisons test. The db/db mice were
administrated with IPA, 5-HT, TUDCA, or SCFAs, i.e., acetate, butyrate, and propionate, individually (n= 8 mice per group). f Bodyweight gain; g escape
latency (s) in place navigation test (the 5th day) (n= 8 mice per group); h mitochondrial DNA levels in brain tissue (n= 8 mice per group); i width of PSD;
and j representative images of ultrastructure of synapse (n= 6 slices per group). Data presented as mean ± SEM. *p < 0.05, **p < 0.01 versus the db/db
group. Significant differences between mean values were determined by one-way ANOVA with Tukey’s multiple comparisons test. See also Supplementary
Figs. 8–11, Supplementary Data 10. Source data are provided as a Source Data file.
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meet the majority of the enormous energy demands made by
neurons47. A sufficient energy supply is required to maintain
neuronal survival, neurotransmission, and the synaptic function.
The fasting process also triggers AMPK activation and mTOR
inactivation, and subsequently stimulates the energy metabolism
and upregulates mitochondrial function to meet the energy
deficiency48,49. We found that IF improved mitochondrial bio-
genesis and energy metabolism-related pathways, consistent with
the upregulation of the AMPK/PGC1α pathway at the protein
level (Fig. 3). Moreover, the microbial metabolites, i.e., 5-HT,
TUDCA, and IPA, have been well reported to be beneficial to
mitochondrial biogenesis and function. 5-HT has been reported
to prevented dopamine-induced oxidative damages of mito-
chondria and synaptosomes45. As mentioned ahead, TUDCA is a
potential neuroprotective agent13,14. It has also been reported that
TUDCA treatment prevented cognitive deficits via improving
mitochondrial function and reducing neuronal apoptosis in an
IPA induced model of Huntington’s disease model14. Similarly, as
one of the microbial metabolites, IPA has been reported to pro-
tect against Aβ-induced neuronal death and restore mitochon-
drial function15,50. SCFAs, generated from dietary fiber by gut
microbiome, has been extensively studied as potential benefits for
brain health51. Butyrate, for instance, was found to be a potential
treatment for autism spectrum disorders as its bioactivity on
enhancing mitochondrial function52. Here, we also found treat-
ments of microbial metabolites also improved diabetes-related
cognitive deficits and increasing mitochondrial biogenesis
(Fig. 6).
Furthermore, the beneficial effects of IF on cognitive function
were suppressed after removing the gut microbiota in diabetic
mice by antibiotics treatment (Fig. 6), suggesting a key role of
microbiota composition and their derived metabolites in med-
iating IF- induced neuronal effects. Mitochondrial biogenesis was
also downregulated by antibiotics in IF-treated mice, which fur-
ther confirms that the restructured gut microbiota was highly
correlated with hippocampal mitochondrial gene expression.
Although there were several reports indicated that metronidazole
could cross the blood–brain barrier and has potential neuro-
toxicity53–55. However, we did not observe any behavioral dis-
orders in both db/m and db/db mice after antibiotics treatment
(Fig. 6; Supplementary Fig. 7). Of note, antibiotics treatment
alone also partly altered the food/water intake, insulin resistance,
and cognitive behaviors in db/db mice (Fig. 6; Supplementary
Fig. 8), in line with a previous report revealing that metronidazole
or vancomycin treatment improves brain insulin sensitivity and
behavioral changes in obese and diabetic mice56. Besides, anti-
biotics treatment reduced the generation of SCFAs and IPA, but
not the levels of TUDCA and 5-HT in IF-treated db/db mice
(Supplementary Fig. 9). These results indicate that the efficiency
of a combined treatment of an IF regimen and antibiotics in
metabolic syndrome needs to be further investigated. It is also
important to further investigate the molecules and pathways that
transmit microbiota changes into the brain, which could lead to
the discovery of new therapeutic targets for metabolism-
implicated cognitive deficits.
Overall, the current research suggests a novel and convincing
link between gut microbiota and cognitive function via microbial
metabolites under the treatment of an IF regimen in diabetic
mice. IF treatment restructured gut microbiome and altered
microbial metabolites, upregulated hippocampus mitochondrial
biogenesis and energy metabolism, protected synaptic ultra-
structure, and alleviated cognition and spatial memory impair-
ments. The impact of IF on changes in microbiota/metabolites/
genes should be further evaluated in clinical trials. Once vali-
dated, IF can be translated into a novel ecological approach for
managing metabolic and neurodegenerative diseases.
Methods
Mice and antibiotics treatment. Male BKS.Cg-Dock7m+ /+ Leprdb/J (stock no:
000642) Homozygous Leprdb/db mice were diabetic, and heterozygous Leprdb/m
mice were used as controls (denoted as db/db and db/m in the text) in this study.
All mice were originally obtained from The Jackson Laboratory (Bar Harbor, ME)
and housed in the Northwest A&F University animal facility under standard
conditions with a strict 12 h:12 h light:dark cycle, humidity at 50 ± 15%, tem-
perature 22 ± 2 °C. The animals were fed ad libitum before the IF was initiated at
4 months of age. Mice were fed a regular chow (AIN-93M, purchased from
TROPHIC Animal Feed High-tech Co. Ltd, Nantong, China) and pure water.
For the first set animals, the db/m mice and the db/db mice were divided in two
subgroups (n= 10), including AL feeding (db/db) and IF (db/db-IF), wherein the
IF mice were deprived of food for 24 h, every other day and were fed ad libitum on
the intervening day for 28 days (Fig. 1a). Bodyweight, food intake, and water
consumption were recorded on fasting day. These animals performed behavioral
tests, and then were killed to collect serum and tissues.
The second set of mice (same grouping with first set, n= 10–11) were treated
with the same IF regimen schedule and then were killed to collect the serum,
hippocampus, gut, and fecal samples for multi-OMICS study. Fecal, serum, and
hippocampus samples were collected to analyze gut microbiome, metabolome, and
RNA sequencing, respectively.
The third set of animals were divided into eight groups, including db/m
(n= 10), db/m-IF (n= 10), db/m-antibiotics (n= 10), db/m-antibiotics-IF
(n= 10), db/db (n= 7), db/db-IF (n= 13), db/db-antibiotics (n= 7), db/db-
antibiotics-IF (n= 13). The different sample size was due to requirement to
distinguish the impact of IF on feeding and fasting day. The IF regimen schedule
was the same as the previously mentioned sets. The antibiotics cocktail (Penicillin
G sodium 0.4 g L−1, metronidazole 0.4 g L−1, neomycin sulfate 0.4 g L−1,
streptomycin sulfate 0.4 g L−1, vancomycin hydrochloride 0.25 g L−1 for db/db
mice, half concentration of same antibiotics for db/m mice) were given in the
drinking water starting 14 days before the IF regimen and throughout the
experiment (Fig. 6a). The 16S rRNA copies in the feces of the animals after
antibiotics treatment were detected with qPCR (Fig. 6b), as previous described57.
All the behavior studies and biochemical samples were collected/detected on the
fasting day of IF regimen. One mouse in the db/db group was drowned during the
water-maze test, and relevant data after that were excluded. For plasma
metabolomics, two samples were excluded due to the poor quality of
measurements.
The fourth set of animals were divided into six groups (n= 8), including db/m,
db/db, db/db-IPA, db/db-5-HT, db/db-TUDCA, db/db-SCFAs. For db/db-IPA, db/
db-5-HT, db/db-TUDCA groups, mice were intraperitoneally injected with IPA
(10 mg kg−1 d−1), 5-HT (1 mg kg−1 d−1), and TUDCA (250 mg kg−1 d−1)
dissolved in saline, respectively. The mice in other groups were injected with same
volume saline. For the SCFAs group, the SCFAs (acetate 67.5 mM, propionate
40 mM, butyric acid 25 mM) were dissolved in the drinking water of the mice.
The mice were treated for 14 days. The treatment was also performed during the
behavioral tests.
After IF regimen, the antibiotics treatment, and metabolites treatment, the
cognitive behavioral assessment was determined with a water-maze test. After
behavioral tests, mice were killed, then the serum and tissues samples were
collected by either snap-frozen by liquid nitrogen and store at −80 °C or directly
stored in 4% paraformaldehyde for histological analysis.
All of the experimental procedures were followed using the Guide for the Care
and Use of Laboratory Animals: Eighth Edition (ISBN-10: 0-309-15396-4). We
have complied with all relevant ethical regulations for animal testing, and research
and protocols were approved by the Northwest A&F University, and BGI
Institutional Review Board on Bioethics and Biosafety (BGI-IRB).
Insulin-tolerance tests and analyses of plasma contents. Insulin-tolerance tests
protocol was modified from our previous research58. The mice were fasted for 6 h
before the tests. The insulin (0.75 U kg−1, Sigma Aldrich, USA) was injected, and
blood glucose was measured before (0 min) and after the injection (15, 30, 60,
120 min) using a OneTouch® SelectSimple™ glucometer (LifeScan Inc., China). For
other content analysis in plasma, all reagents and kits source and identifiers were
listed in Supplementary Table 1. The plasma insulin, leptin, 5-HT, and LPS were
detected using ELISA kits purchased from Xinle Bio Co.,Ltd., Shanghai, China.
The homeostasis model assessment of insulin resistance (HOMA-IR) was calcu-
lated as (fasting insulin concentration (mU L−1) × fasting glucose concentration
(mg dL−1) × 0.05551)/22.5.
H&E and immunochemistry staining. For H&E staining, the adipose and gut
(colon) tissues were embedded in paraffin for staining with hematoxylin and eosin.
The adipocytes sizes were measured by Image J (developed by Wayne Rasband
from NIH, USA) software with Adipocytes Tools plugins after pictures were
recorded by light phase contrast microscopy. The immunohistochemical staining
was performed according to previous study59. The fixed brain and gut sections
were exposed to the primary antibodies at 4 °C overnight; the information of
primary antibodies is shown in the Supplementary Table 1. After incubation, the
sections were washed three time with PBS and incubated with biotinylated goat
anti-rabbit or goat anti-mouse diluted in a secondary antibody dilution buffer.
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After staining nuclei by hematoxylin, neutral resin was used for sealing the sec-
tions. Then, the IHC staining images were obtained using an inverted fluorescent
microscope (×400).
Morris water-maze tests. The Morris water maze is one of the most widely used
tests in behavioral neuroscience for studying the psychological processes and
neural mechanisms of spatial learning and memory. The protocol was modified
from our previous research and detailed described as following60. The apparatus
consists of a large circular pool, 1.5 meters in diameter and a height of 35 cm (XR-
XM101, Shanghai Xinruan Information Technology Co. Ltd, Shanghai, China),
containing water at around 25 °C. The mice received four habituation trainings on
day 0. The platform was visible (2 cm above the water surface), and the water was
un-dyed. The water was then made opaque by adding white-dye (food-grade
titanium dioxide) that helped to hide the submerged platform (day 1–day 6). Test
trials were conducted for 5 consecutive days (day 1–day 5). On day 6, a probe trial
was conducted in which mice were placed in the pool for 60 s without the platform
and the time that was spent in the target quadrant, the latency to the platform and
the number of platform crossings were measured. All the data were recorded
automatically using a video tracking system (SuperMaze software, Shanghai Xin-
ruan Information Technology Co., Ltd, China).
Electron microscopy for the structural analysis of the hippocampus. A
transmission electron microscope (TEM) analysis was done after the collection of
CA1 region of hippocampus. The hippocampus was split and treated in a cold
fixative solution made of 2.5% glutaraldehyde (pH 7.2) at 4 °C for 4 h. After
washing with PBS (0.1 M, pH 7.2) thrice. Then the specimens were post-fixed in
1%OsO4 (in 0.2 M PBS, pH 7.2) at 4 °C for 1 h and washed again with PBS (0.1 M,
pH 7.2) thrice. The specimens were dehydrated for 15–20 min each in a graded
series of ethanol solutions (30, 50, 70, 80, 90, and 100%) and then transferred to
acetone for 20 min incubation. Materials were then permeated in an acetone–resin
mixture (1:1) for 1 h at 25 °C and then transferred to an acetone–resin mixture
(1:3) overnight. Ultrathin sections were placed in the regions which were closed to
the embedded blocks and kept away from the dorsal rim area, stained with uranyl
acetate and alkaline lead citrate for 15 min, and then observed using JEM-1230
TEM (JEOL, Tokyo, Japan) at 80 kV and acquired using a side-inserted BioScan
Camera (Veleta, EMSIS GmbH, Germany).
Ussing chamber assay. Ussing chambers are a common tool to evaluate the gut
barrier ex vivo. Directly after dissection of the intestine, 1.5 cm pieces of the
jejunum (the center of the small intestine) were opened along the mesenteric
border and mounted as flat sheets in the Ussing chambers separating the chamber
into two halves (BeiJing KingTech technology Co.Ltd, Beijing, China). Luminal and
serosal surfaces were continuously exposed to carbogen-gassed Krebs buffers
(CaCl2·2H2O 7.35 g, NaCl 13.67 g, KCl 7.01 g, NaHCO3 4.2 g, MgCl2·6H2O 4.88 g,
glucose 3.96 g, NaH2PO4·2H2O 3.74 g, dissolved in 2 L ddH2O, pH 7.4) at 37 °C.
Tissues were equilibrated for 45 min in the presence of 0.09 g L−1 fluorescein on
the luminal side. For permeability measurements, the fluorescence intensity of the
serosal buffer was determined at 0, 15, 30, 45, and 60 min and used to calculate
permeability as expressed in gradient.
Western blots. The protein of gut and brain tissue were extracted using a protein-
extraction reagent. The total tissue proteins (n= 3) were separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE), and then transferred onto a
polyvinylidene fluoride (PVDF) membrane by using a wet transfer apparatus.
Appropriate antibodies were used and the immunoreactive bands were visualized
with an enhanced chemiluminescence reagent. The information of primary anti-
bodies is shown in Supplementary Table 1. Quantification of the western blots
results using the band densitometry analysis was performed with Quantity One
software.
qRT-PCR. The total RNA extracted from frozen tissues using TRIzol reagent
(Jingcai Bio., Xi’an, Shaanxi, China) was determined and reverse transcribed for
real-time PCR. Relative mRNA expression was quantified using SYBR Green dye
(TB Green Premix Ex Taq II) and specific primers. Real-time PCR was carried out
in a CFX96TM real-time system (Bio-Rad). The following conditions were used:
95 °C for 10 min, then 95 °C for 15 s, and 60 °C for 1 min in 40 cycles. The 2−ΔΔCT
method was used to analyze the relative changes in gene expression. For the
mitochondrial biogenesis, the total DNA extracted from brain tissue using a DNA
extraction kit (Bioteke Co., Beijing, China) were also determined by real-time PCR.
The mitochondria number were indicated by the lower ratio of mitochondrial
DNA (mtDNA, COX2) to nuclear DNA (nDNA, globin). Reagent information and
primer sequences are shown in Supplementary Table 1.
We filtered and trimmed the reads using Trimmomatic v0.38. Clean reads were
mapped to the Mus musculus genome sequence (ftp://ftp.ncbi.nlm.nih.gov/
genomes/all/GCF/000/001/635/GCF_000001635.26_GRCm38.p6) using Hisat2 v2-
2.1.0. The reads of each sample were then assembled into transcripts and compared
with reference gene models using StringTie v1.3.4d. We merged the 31 transcripts
to obtain a consensus transcript using a StringTie-Merge program. Transcripts that
did not exist in the CDS database of the Mus musculus genome were extracted to
predicted new genes. The gene expression FPKM values were calculated using
StringTie based on the consensus transcript. DEG analysis was performed using
Ballgown v2.12.0, an R programming-based tool designed to facilitate flexible
differential expression analysis of RNA-Seq data. Only genes with fpkm >1 (n= 10)
were subjected to analysis and the differential expression genes was determined
(FDR-p < 0.05).
An unsupervised co-expression network analysis of all genes was performed
using R package WGCNA v1.64. The signed scale-free topology overlap matrix was
computed, and co-expression modules were defined from this network. For each
identified module, the hub genes were defined by module connectivity (Pearson’s
correlation >0.8) and correlations between each intra-module gene and treatments
(correlation >0.85). The co-expression network was visualized using the Cytoscape.
The GO and KEGG pathways were annotated using WebGestalt (http://www.
webgestalt.org/2019/) (false discovery rate FDR-adjusted p < 0.05). A detailed
description of data processing and analysis is provided in Supplementary
Information.
16S rRNA Microbiome sequencing. Fecal samples were collected from respective
groups either at the beginning or before the behavioral tests. The total cellular DNA
was extracted with the E.Z.N.A. Stool DNA Kit (Omega) according to the company
instructions. The bacterial hypervariable V3–V4 region of 16S rRNA was chosen
for MiSeq (Illumina, CA, USA) paired-end 300 bp amplicon analysis using primer:
341_F: 5′-CCTACGGGNGGCWGCAG-3′ and 802_R: 5′-TACNVGGGTATCTA
ATCC-3′. The library preparation followed the method published previously61.
The raw reads were merged and trimmed, following by removal of chimera and
constructing zero-radius Operational Taxonomic Units (zOTUs) with UNOISE
implemented in Vsearch (v2.6.0). The green genes (13.8) 16S rRNA gene database
was used as a reference for annotation. Detailed algorithms and parameters are
given in Supplementary Information. All the samples were rarified to 28,257 counts
for alpha diversity index calculation. The raw OTU table was normalized with
cumulative sum scaling62 (CSS) to calculate Bray Curtis, unweighted and weighted
Unifrac distance, followed by a permutation test (Vegan:adonis) to detect
differences among intervention groups. Constrained analysis of principal
coordinate (CAP, R package “vegan”) was applied to identify the influence of mice
gene type and IF on microbiota and time was introduced as a partial term to
remove the background effect of time. CSS-normalized OTU data were used to
calculate relative abundance and summarized in different levels. Specific taxa
comparisons among groups were analyzed using the analysis of composition of
microbiomes (ANCOM). FDR-p < 0.05 was considered to be a significant
difference. We also computed Pearson correlations between centered log-ratio
transformed relative abundance of genera and bodyweight, blood glucose, food
intake, water intake, LPS, leptin, GABA, 5-HT, insulin, and fecal SCFAs. Rarified
OTU data were used to predict functional gene with PICRUSt (v1.1.3). Predicted
gene was annotated with KEGG at different levels, and the significantly abundant
pathways were identified by edgeR with FDR-p < 0.1.
SCFAs analysis. The concentrations of SCFAs (acetate, propionate, and butyrate)
were determined with a Shimadzu GC-2014C gas chromatograph (Shimadzu
Corporation, Kyoto, Japan) equipped with a DB-FFAP capillary column (30 m ×
0.25 µm × 0.25 mm) (Agilent Technologies, Wilmington, DE, USA) and flame
ionization detector. Approximately 200 mg of the fecal content sample was
homogenized with 1 ml of distilled water; then, 0.15 mL of 50% H2SO4 (w/w) and
1.6 mL of diethyl ether were added. After the samples were incubated at 4 °C for 30
min, they were centrifuged at 8000 rpm for 5 min. The organic phase was collected
and analyzed using gas chromatography as follows. The initial temperature was
50 °C, which was maintained for 3 min and then raised to 130 °C at 10 °C per min,
increased to 170 °C at 5 °C per min, increased to 220 °C at 15 °C per min and
held at this temperature for 3 min. The injector and the detector temperature were
250 °C and 270 °C, respectively.
Untargeted metabolomics. Plasma samples were collected after the animals were
killed, and were stored at −80 °C until analysis. Samples were analyzed using an
ultra-performance liquid chromatography (UPLC) system and a high-resolution
tandem mass spectrometer Xevo G2 XS QTOF (Waters, UK). Reverse-phase
chromatography was employed, using both positive and negative electrospray
ionization modes (ESI, RP+ and RP−). A 10 µl of the sample solution was injected
on an ACQUITY UPLC HSS T3 column (100 mm × 2.1 mm, 1.8 μm, Waters, UK).
The column oven was maintained at 50 °C. The flow rate was 0.4 ml per min and
the mobile phase consisted of solvent A (water+ 0.1% formic acid) and solvent B
(acetonitrile+ 0.1% formic acid). Gradient elution conditions were set as follows:
0–2 min, 100% phase A; 2–11 min, 0% to 100% B; 11–13 min, 100% B; 13–15 min,
0% to 100% A. ESI source was operated using the following conditions: for the
positive ion mode, the capillary and sampling cone voltages were set at 3.0 kV and
40.0 V, respectively. For the negative ion mode, the capillary and sampling cone
voltages were set at 2.0 kV and 40.0 V, respectively. The mass spectrometry data
were acquired in Centroid MSE mode. The TOF mass range was from 50 to 1200
Da, and the scan time was 0.2 s. For the MS/MS detection, all precursors were
fragmented using 20–40 eV, and the scan time was 0.2 s. During acquisition, the LE
signal was taken every 3 s to calibrate the mass accuracy.
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Samples were analyzed in one batch with a randomized injection order. The
stability and functionality of the system was monitored throughout all the
instrumental analyses using quality controls, i.e., the pooling of all samples
acquired at the beginning of analytical sequence and after every ten injections. Data
preprocessing was performed using Progenesis QI (version 2.2). In total, 6295 and
6893 metabolic features were detected. A support vector regression-based
normalization was performed to minimize unwanted variations in feature
intensities, resulting in 5604 and 5230 features in RP+ and RP−, respectively, with
relative standard deviations below 20%63. They were considered as qualified
features and were subjected to statistics. P-values for fold change were adjusted for
multiple testing using Benjamini–Hochberg false discovery rate (FDR). Principal
component analysis was performed on auto-scaled intensities (mean= 0, standard
deviation= 1) of all quantified metabolite features detected in RP+ and RP−,
respectively using R package “mixOmics”.
Metabolite identification was carried out based on accurate mass and product
ion spectrum matching against online databases and literature. The list of microbial
cometablites (i.e., metabolites whose levels were modified by gut microbiota) was
determined according to Rowan et al.12. Annotated microbial metabolites are
provided in Source data file of Fig. 4.
Integrated multi-OMICS analysis. Multivariate predictive modeling on each omics
data set was conducted using partial least square-discriminant analysis incorporated
into a repeated double cross-validations framework (rdCV-PLSDA)34. Outperforming
the standard cross-validation, the double cross-validations procedure separates cross-
validations into an outer “testing” loop, and an inner “tuning” (or validation) loop to
further reduce bias from overfitting models to experimental data. To gain a robust
and reliable estimate of model performance, 200 repetitions of the outer cross-
validations loop was performed, followed by permutation analysis (n= 1000)34,64.
A multivariate dimension reduction method, DIABLO (Data Integration
Analysis for Biomarker discovery using a Latent component method for Omics),
was employed for multiple omics integration33. A random use of full design matrix
was applied to look for linear combinations of variables from each omics data set
that are maximally correlated. A tuning procedure was applied to determine the
optimal number of key variables in each data set to be selected with a minimum
misclassification rate. Model performance was then evaluated by tenfold cross-
validation. The detailed step-by-step workflow of DIABLO analysis is provided in
Supplementary Information.
Statistical analysis. Other than RNA sequencing, gut microbiome, and metabo-
lome data, other data were reported as mean ± SEM, significant differences between
mean values were determined by Student’s t test and one-way ANOVA. The data
for antibiotics treatment experiments were determined with two-way ANOVA with
IF and antibiotics as factors. A post hoc test was performed using Tukey’s test for
multiple comparison test by Graphpad Prism 6.0 software. Other software infor-
mation employed in this study is deposited in Supplementary Information. The
measurements were taken from distinct samples. Means were considered to be
statistically significant, if p < 0.05.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data file underlying Figs. 1–6 and Supplementary Figs. 1–10 ware provided
as a Source data file and some OMICs data used in these figures were also deposited as
Supplementary Data 1–10. The accession number for the entire RNA-seq data set
reported in this manuscript is GSE125387. The accession number for the entire 16 S
rRNA sequencing data set reported in this manuscript is SRP181000. The RNA-seq
and 16S rRNA sequencing data that support the findings of this study have been
also deposited in the CNSA (https://db.cngb.org/cnsa/) of CNGBdb with accession
number CNP0000608. Raw data were also deposited in figshare data set as follows:
https://figshare.com/s/58ccac4aa614dd4ade84.
Code availability
All the software and R programming codes used in current study are ether commercial or
have been previously published. Detailed information is provided in the text and in
Supplementary methods. No custom code has been developed and applied in current
study. A step-by-step R markdown file for integrative modeling is also provided in
Supplementary Information, together with the multi-OMICs data set.
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